期刊文献+

质子磁共振波谱在帕金森病患者纹状体中的应用研究 被引量:5

Study on Changes of Proton Magnetic Resonance Spectroscopy(1H-MRS) in Corpus Striatum of Patients with Parkinson's Disease
下载PDF
导出
摘要 目的:利用质子磁共振波谱(1H-MRS)技术研究帕金森病(PD)患者纹状体的代谢变化,评价H-MRS1用于PD的病理生理研究和诊断的价值。方法:采用H-MRS检测15例PD与12例年龄匹配的健康对照者双侧纹状体1N-乙酰天门冬氨酸(NAA)、胆碱复合物(Cho)及肌酸复合物(Cr)含量,比较NAA/Cr、Cho/Cr、NAA/Cho比值。结果:PD组NAA/Cr、Cho/Cr、NAA/Cho分别为(1.2±0.15)、(0.9±0.13)、(1.1±0.14),对照组分别为(1.8±0.12)、(0.9±0.15)、(1.4±0.13)。PD组NAA/Cr、NAA/Cho值减低,与对照组比较差异有统计学意义(P<0.05)。结论:NAA/Cr、NAA/Cho值降低是评估PD患者神经元功能损害的重要指标。1H-MRS对PD患者双侧纹状体进行检测,可以为PD患者的病理生理改变和诊断提供重要信息。 Objective To study the metabolism of corpus striatum in patients with Parkinson disease(PD) by proton magnetic resonance spectroscopy(1H-MRS),and evaluate the clinical value of the technique in the pathophysiological process and the diagnose of PD.Methods The contents of N-acetylaspartate(NAA),choline compound(Cho) and creatine compound(Cr) in corpus striatum of 15 PD patients and 12 age-matched healthy controls were examined with proton MRS and the ratios of NAA/Cr,Cho/Cr and NAA/Cho were calculated.Results The ratios of NAA/Cr,Cho/cr and NAA/Cho in the PD patients were(1.2±0.15),(0.9±0.13),(1.1±0.14) respectively,and those of the healthy controls were(1.8±0.12),(0.9±0.15),(1.4±0.13).The ratios of NAA/Cr,NAA/Cho in PD patients showed significant reduction compared with the controls(P 〈 0.05).Conclusion The reduction of NAA/Cr and NAA/Cho ratio in PD patients may indicate the dysfunction of the neurons.Proton MRS may provide an important information to understand the pathophysiological process of PD and to diagnose PD by detection bilateral Corpus Striatum
出处 《深圳中西医结合杂志》 2011年第4期204-207,共4页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
基金 深圳市科技计划项目(200103099)
关键词 帕金森病 纹状体 磁共振波谱学 Parkinson's disease Corpus striatum Magnetic resonance spectroscopy
  • 相关文献

参考文献9

二级参考文献23

  • 1张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 2Gujar SK, Maheshwari S, Bjorkman-Burtscher I, et al. Magnetic resonance spectroscopy [J]. J Neuroophthalmol, 2005,25(3):217-226. 被引量:1
  • 3Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes[J]. Funct Neurol,2007,22(2) :75-79. 被引量:1
  • 4Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders[J]. Mov Disord, 2003,18 (5):467-486. 被引量:1
  • 5Morrish P. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease[J]. Mov Disord,2005,20(1) : 117. 被引量:1
  • 6Antonini A,Benti R,de NotaRis R,et al. 123 I-Ioflupane/Spect binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supanuclear palsy[J]. Neurol Sei, 2003,24 (3) : 149- 150. 被引量:1
  • 7Cropley VL, Fujita M, Bara-Jimenez W, et al. Pre- and postsynaptie dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [ 18F] FDOPA[J]. Psychiatry Res, 2008, 163(2) : 171-182. 被引量:1
  • 8Podell M, Hadjiconstantinou M, Smith MA, et al. Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism[J]. Exp Neurol,2003,179(2) : 159-166. 被引量:1
  • 9Bertolino A,Frye M,Callicott JH,et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging[J]. Biol Psychiatry,2003,53(10) : 906-913. 被引量:1
  • 10Camieioli RM, Hanstoek CC, Bouehard TP, et al. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease [J]. Mov Disord, 2007,22 (3) : 382-386. 被引量:1

共引文献19

同被引文献35

  • 1许化致,孙波,戴建平.3.0T磁共振正常人脑深部核团T2信号与年龄的关系研究[J].中国医学影像技术,2006,22(5):678-681. 被引量:9
  • 2张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 3Litvan I,Bhatia KP,Burn DJ,et al.SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders[J]. Mov Dis-ord,2003,18(5):467-472. 被引量:1
  • 4Morrish P.The meaning of negative T SPECT and F-Dopa PET scans in patients with clinical Parkinsonian disease[J]. Mov Disord,2005,20(1):117. 被引量:1
  • 5Rango M,Canesi M,Ghione I,et al.Parkinson′s disease,chronic hydrocarbon exposure and striatal neuronal damage:a 1H-MRS study[J].Neurotoxicology,2006,27(2):164-168. 被引量:1
  • 6Abe K,Terakawa H,Takanashi M,et al.Porton magnetic resonance spectroscopy of patients with Parkinsonism[J].Brain Research Bulletin,2000,52(6):589-595. 被引量:1
  • 7O'Neill J,Schuff N,Marks WJ Jr,et al.Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson 's disease[J]. Mov Disord,2002,17(5):917-927. 被引量:1
  • 8Geng Dy,Li YX,Zee CS,et al.Magnetic resonace imaging-based v 6olumetric analysis of ganglia nuclei and substantia nigra in patients with Parkinson′s disease[J].Neurosurgey,2006,58(2):256-262. 被引量:1
  • 9杨正汉,冯逢,王霄英,等.磁共振成像技术指南[M].北京:人民军医出版社,2007:85-88. 被引量:193
  • 10Stankiewicz J, Panter SS, Neema M, et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications [J]. Neurotherapeutics, 2007, 4(3):371-386. 被引量:1

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部